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Coxsackievirus A21 (CAVATAK™) is a bio-selected
oncolytic immunotherapy virus. Following intratumoral
(i.t) injection, CAVATAK selectively infects ICAM-1-
expressing tumor cells, resulting in tumor cell lysis and a
systemic immune-mediated anti-tumor response. A Phase
II trial of i.t delivered CAVATAK (NCT01227551) in
advanced melanoma patients has highlighted antitumor
activity in both injected and distant non-injected lesions.
Such responses have occurred at times when no circulat-
ing infectious CAVATAK was detected in patient serum
and in an environment of high levels of anti-CAVATAK
neutralizing antibodies. In further support of the genera-
tion of CAVATAK-mediated immune anti-tumor activity
is the identification of a possible novel serum cytokine
signature of elevated levels of IL-8 and IFN-g in treated
patients associated with tumor inflammation and systemic
tumor response. Blockade of programmed death-1 (PD-1)
in patients with metastatic melanoma has resulted in
substantial tumor responses via a mechanism involving
reversal of tumor-induced T cell suppression. We
hypothesized that a combination of CAVATAK and PD-1
blockade may enhance anti-tumor responses, potentially
leading to improved clinical activity. Preclinical studies in
C57BL mice were conducted to assess the anti-tumor
activity of CAVATAK and anti-mouse PD-1 (mPD-1)
mAb in a B16-ICAM-1 melanoma immune competent
mouse model. B16-ICAM-1 cells are murine melanoma
B16 cells stably transfected to express human ICAM-1
allowing CAVATAK binding and cell infection. CAVA-
TAK was administered i.t, while anti mPD-1 mAb was
delivered intraperitoneally. Following treatment of the pri-
mary cutaneous B16-ICAM-1 tumor with 8 cycles of
CAVATAK injections and 4 cycles of anti-PD-1mAb,
mice were challenged with additional subcutaneous
administration of B16 cells. Significant single agent anti-
tumor activities against the primary B16-ICAM-1 tumor
were observed in mice treated with either CAVATAK or
anti-PD-1 mAb relative to saline controls. Combination of
CAVATAK and anti-PD-1 mAb mediated significantly
greater anti-tumor activity and offered greater survival
benefit when compared to use of either agent alone. Of
particular interest was the finding that a combination of
CAVATAK and anti-PD-1 mAb was able to noticeably
delay the onset of palpable tumor development following
B16 cell challenge when compared to all other single
agent treatment regimes. The significant anti-tumor activ-
ity mediated by the combination of CAVATAK and the
checkpoint inhibitor antibody (anti-PD-1) observed in the
presented murine melanoma model supports clinical
evaluation of such an immunotherapeutic combination
treatment regimen in patients with advanced melanoma.
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